Wedbush analyst David Nierengarten maintained a Buy rating on BridgeBio Oncology Therapeutics on December 18 and set a price target of $25.00. The company’s shares closed last Friday at $12.06.

If you're a business owner, your personal auto insurance won't cover cars, trucks, or other vehicles you use for work. Commercial auto insurance can provide liability, collision and comprehensive ...

If you click on links we provide, we may receive compensation. Including Levi’s jeans, Apple AirTags, and more Amazon (4) Like everyone else, the PEOPLE shopping team spends more time than we’d like ...

We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Myles is a former senior insurance editor for Investopedia. He oversaw the strategy ...

Ranked by Metro square feet broken ground on, 2023-2025 Ranked by 2025 Central Ohio remodeling sales volume Showcase your company news with guaranteed exposure both in print and online Get ready for ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead ...

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small ...

About BridgeBio Oncology Therapeutics Inc. Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on advancing a next-generation pipeline of novel small ...

The Qualified Commercial Clean Vehicle Credit tax credit under Section 45W of the IRS tax code may be gone, but it’s not forgotten! A number of states and utilities are stepping up with their own ...